How effective is dapoxostat in treating anemia caused by chronic kidney disease (CKD)?

Daprodustat (Daprodustat), as an innovative hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has received great attention in the field of treating anemia related to chronic kidney disease (CKD) in recent years. Patients with chronic kidney disease are prone to anemia due to reduced renal synthesis of erythropoietin (EPO), and traditional treatment mainly relies on exogenous EPO injections. Daprostat activates the HIF pathway by simulating a hypoxic environment, thereby promoting the natural secretion of endogenous EPO, while regulating the expression of genes related to iron metabolism and improving erythropoiesis. This mechanism not only helps to steadily increase hemoglobin levels, but may also reduce reliance on intravenous iron therapy.

A number of large overseas phase III clinical trials (such asASCEND-D study and ASCEND-ND study) have shown that daprostat can effectively maintain hemoglobin levels within the target range in patients with dialysis-dependent and non-dialysis-dependent chronic kidney disease. Compared with traditional erythropoietin preparations (such as Irexipan, Dalbitux, etc.), the efficacy is not inferior, and some patients reported an improvement in their quality of life. It is particularly worth mentioning that as an oral preparation, daprostat greatly improves patients' medication convenience and compliance compared with injectable ESA medications, and reduces the occupation of medical resources.

In terms of safety, although the incidence rates of major adverse cardiovascular events (such as myocardial infarction and stroke) between daprostat and traditional ESA drugs are generally similar, risks such as hypertension, thrombosis and electrolyte imbalance still need to be closely monitored. In addition, the study also suggests that long-term use of HIF-PHI drugs may have potential concerns about increasing the incidence of tumors. However, there is currently no conclusive evidence that daprostat directly increases the risk of cancer, and further long-term follow-up verification is still needed.

Based on current data, daplestat is considered an effective, convenient, and generally safe new option, especially for patients with chronic kidney disease anemia who want to avoid frequent injections and improve treatment compliance.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat